Inhaled drug developer MannKind Corporation announced that the company has expanded its capacity for commercial manufacturing of highly potent dry powder formulations at its facility in Danbury, Connecticut, USA. The new manufacturing suite includes bulk powder formulation and filling for high potency powders such as epinephrine, the company said. According to … [Read more...] about MannKind adds high potency DPI formulation manufacturing capacity
Business
Seurat Therapeutics to use Kurve Technology device for intranasal migraine therapy
Kurve Technology has announced that Seurat Therapeutics will use Kurve's intranasal delivery technology for Seurat's IGF-1 nasal aerosol for the treatment and prevention of migraines. Details of the development and collaboration agreement were not disclosed. In October 2018, Seurat announced that it had received a ~$510,000 grant from the National Institute of … [Read more...] about Seurat Therapeutics to use Kurve Technology device for intranasal migraine therapy
Liquidia to develop additional inhaled drugs
Liquidia Technologies has announced amendments to its 2012 collaboration agreement with GlaxoSmithKline that gave GSK the rights to develop inhaled dry powder formulations based on Liquidia's PRINT particle manufacturing technology. Under the terms of the amended agreement, Liquidia gets development and commercialization rights to three PRINT-based inhalation … [Read more...] about Liquidia to develop additional inhaled drugs
Insmed raises additional $25.6 million in public offering
Insmed has announced that it raised ~$25.6 million in net proceeds through the sale of additional shares after a public offering earlier this year netted approximately $235.5 million. The underwriters of that offering had a 30-day option to purchase up to 1,042,307 additional shares of common stock from the company and up to 400,000 shares of common stock from … [Read more...] about Insmed raises additional $25.6 million in public offering
Glenmark gets CRL for Ryaltris, acquires Brazilian rights to Breezhaler DPIs
Glenmark Pharmaceuticals has revealed that the FDA issued a complete response letter to the company's NDA for Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray. The agency accepted the NDA for Ryaltris in August 2018 with a PDUFA date of March 21, 2019. According to Glenmark, the CRL references issues related to the drug master file for one of the … [Read more...] about Glenmark gets CRL for Ryaltris, acquires Brazilian rights to Breezhaler DPIs
Syqe launches cannabis inhaler in Israel
According to Syqe Medical, the company has received regulatory approval from the Israeli Ministry of Health to launch its metered-dose cannabis inhaler in Israel for the treatment of pain. The inhaler, which was previously available only for hospital use, will now be available to licensed patients. In 2016, the company announced that Teva would distribute the … [Read more...] about Syqe launches cannabis inhaler in Israel
Boehringer Ingelheim opens new Respimat manufacturing facility
Boehringer Inhgelheim has opened a new €120 million Respimat manufacturing facility in Sant Cugat del Vallés, Spain, near Barcelona, the company said. The 17,000 sq m plant is expected to produce 25 million units per year, over half of Respimat global annual sales. The facility will create approximately 200 new jobs. Boehringer Ingelheim Spain CEO Peter Ploeger … [Read more...] about Boehringer Ingelheim opens new Respimat manufacturing facility
Theravance and Mylan add China to nebulized revefenacin agreement
Theravance Biopharma and Mylan have expanded their 2015 development and commercialization agreement for nebulized revefenacin (formerly TD-4208) to include China, Hong Kong, Macau, and Taiwan. The 2015 agreement included all markets except for China and the additional territories that have now been added. Mylan will pay Theravance $18.5 million up front and up to … [Read more...] about Theravance and Mylan add China to nebulized revefenacin agreement
Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray
Upsher-Smith Laboratories has acquired the US rights to Tosymra sumatriptan nasal spray from Dr. Reddy's Laboratories, the companies have announced. The FDA approved Dr. Reddy's subsidiary Promius Pharma's NDA for Tosymra in January 2019. The agreement, which also covered US rights to Zembrace Symtouch sumatriptan injection, included a $70 million upfront payment, … [Read more...] about Upsher-Smith acquires US rights to Tosymra sumatriptan nasal spray
Insys Therapeutics files for bankruptcy, plans to sell all assets
Insys Therapeutics has filed for Chapter 11 bankruptcy and plans to sell "substantially all of the company’s assets," the company said. Insys's pipeline includes inhaled dronabinol, intranasal epinephrine, and intranasal naloxone. NDA submissions for the nasal sprays had been planned for 2019. The bankruptcy filing comes in the wake of legal troubles related to … [Read more...] about Insys Therapeutics files for bankruptcy, plans to sell all assets